In Phase I we developed a model system and a prototype Salt Sensitivity Assay to establish proof-of-principle . In Phase II we propose the evaluation of the prototype that will quantitatively measure our biomarker in the target population. An ideal biomarker for salt sensitivity would be one that is linked to the underlying cause of salt sensitivity and not disease symptoms. It is our hypothesis that this biomarker can be accurately measured using a monoclonal antibody-based direct quantitative ELISA. The assay will allow physicians to identify salt sensitivity in newly diagnosed hypertensive patients so that appropriate therapy can begin as early as possible. The information gained from this accurate screening test will lead to basic research investigations of the biological mechanisms underlying salt sensitivity and its pathophysiological consequences such as hypertension, CHF, renal disease, and edema. We request Phase II support so that we can evaluate our prototype Salt Sensitivity Assay in a pivotal study with the ultimate goal of obtaining FDA approval. In addition, our proposal also addresses several research questions and explores an exciting new secondary application of our assay in the assessment of renal function. ? ? Project Narrative ? Hypertension affects almost 50 million people in the United States, which places them at higher risk for chronic renal failure and cardiovascular disease. Of those affected, about half are salt-sensitive. We will develop an ELISA for hypertensive people that can be used to distinguish between salt sensitive and salt resistant individuals. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK070374-03
Application #
7395153
Study Section
Cellular and Molecular Biology of the Kidney Study Section (CMBK)
Program Officer
Moxey-Mims, Marva M
Project Start
2005-04-01
Project End
2010-02-28
Budget Start
2008-03-05
Budget End
2009-02-28
Support Year
3
Fiscal Year
2008
Total Cost
$504,066
Indirect Cost
Name
Sequela
Department
Type
DUNS #
189577070
City
Pewee Valley
State
KY
Country
United States
Zip Code
40056
Rozenfeld, Julia; Tal, Osnat; Kladnitsky, Orly et al. (2013) Pendrin, a novel transcriptional target of the uroguanylin system. Cell Physiol Biochem 32:221-37
Rozenfeld, Julia; Tal, Osnat; Kladnitsky, Orly et al. (2012) The pendrin anion exchanger gene is transcriptionally regulated by uroguanylin: a novel enterorenal link. Am J Physiol Renal Physiol 302:F614-24
Rozenfeld, Julia; Efrati, Edna; Adler, Lior et al. (2011) Transcriptional regulation of the pendrin gene. Cell Physiol Biochem 28:385-96